The first agreement will cost the healthcare company $209.2 million for incorrectly billing Medicaid, Medicare and other programs for insulin pens dispensed to people the company knew did not need the treatments.

The second settlement requires the company to pay $60 million for allegedly overbilling Medicaid by failing to offer reduced drug prices through its discount program.

Read the full article from Health Payer Intelligence.